Pharmaceutical developer Fujisawa USA of Deerfield, IL, announced March 31 that it is selling its generics business to American Pharmaceutical Partners of Santa Monica, CA. Fujisawa plans to retain its proprietary drug business, which includes the
Pharmaceutical developer Fujisawa USA of Deerfield, IL, announced March 31 that it is selling its generics business to American Pharmaceutical Partners of Santa Monica, CA. Fujisawa plans to retain its proprietary drug business, which includes the cardiac stress agent Adenoscan and cardiac therapy drug Adenocard. Both products are licensed from Medco Research of Research Triangle Park, NC. Fujisawa expects to complete the sale of its generics business by May. At that point, Fujisawa will restructure its remaining proprietary pharmaceutical business as a new corporate entity, Fujisawa Healthcare.
